Merck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology drugs to its pipeline as it searches for successors to cancer blockbuster Keytrud
Rare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Pharmaceuticals, a division of Canada’s Novelion.
Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts fol
M&A (mergers and acquisitions) in digital health almost ground to a halt in Q1 this year, according to new figures from analysts Mercom Capital, which also showed a dip in venture capit
Hu-manity.co has acquired Betterpath, a New York-based firm that allows patients and other users to search, find, and improve healthcare data that is currently difficult to access.